Ocular Hypertension Clinical Trial
Official title:
An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness
Verified date | August 2017 |
Source | Ordination Dr. Hommer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Studies have shown that ocular surface disease (OSD) is common among patients with glaucoma
with a prevalence of 50% or more. The percentage of affected patients appears to increase
with increasing number of topical anti-glaucoma products instilled. Both pre-clinical and
clinical work has indicated that the preservatives used in anti-glaucoma drops, particularly
benzalkonium chloride, are mainly responsible for this detrimental effect. As such more and
more anti-glaucoma drugs without preservatives entered the market.
To prove that switching from preserved to unpreserved antiglaucoma medication improves the
signs and symptom of OSD is, however, not easy. This is on the one hand related to the
physiological variability of these parameters over time and on the other hand to the poor
association between signs and symptoms. Recently, a new method for measuring tear film
thickness (TFT) using ultra-high resolution optical coherence tomography (OCT) has been
introduced. Using this method, it has been shown that there is a correlation between reduced
TFT and OSD symptoms. In the present study, it is hypothesized that changing patients who are
on preserved prostaglandin formulations to preservative free tafluprost may be associated
with an increase in TFT.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 30, 2017 |
Est. primary completion date | April 25, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Men and women aged over 18 years - Diagnosed primary open angle glaucoma treated with preserved prostaglandins for at least 6 months OR - Patients with ocular hypertension treated with preserved prostaglandins for at least 6 months - IOP = 21 mmHg in the study eye at the screening examination (under treatment) - Mean TFT at the screening visit = 6µm in the study eye - At least 2 symptoms of dry eye syndrome in the study eye (itching, stinging, blurred vision, foreign body sensation, debris, conjunctival redness) since at least one month - Tear break up time = 10sec Exclusion Criteria: - Participation in a clinical trial in the 3 weeks before the screening visit - Severe visual field loss as defined as an MD of -15 or worse in the study eye - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator - Sjögren's syndrome - Stevens-Johnson syndrome - Presence or history of a severe ocular condition that will interfere with the study aim as judged by the clinical investigator - Presence or history of allergic conjunctivitis - Treatment with corticosteroids in the 4 weeks preceding the study - Wearing of contact lenses - Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except glaucoma medication or topical lubricants - Ocular infection - Ocular surgery in the 6 months preceding the study (except laser trabeculoplasty) - Pregnancy, planned pregnancy or lactating - Contraindication against the use of topical prostaglandin therapy |
Country | Name | City | State |
---|---|---|---|
Austria | Ordination Dr. Hommer | Vienna |
Lead Sponsor | Collaborator |
---|---|
Ordination Dr. Hommer |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tear film thickness | Measurement of tear film thickness using OCT | Change from baseline tear film thickness at 4 and 12 weeks | |
Secondary | Intraocular pressure (IOP) | Measurement of IOP using Goldmann applanation tonometry | Change from baseline IOP at 4 and 12 weeks | |
Secondary | Ocular Surface Disease Index (OSDI) | Subjective symptom questionnaire | Change from baseline OSDI at 4 and 12 weeks | |
Secondary | Dry-Eye Related Quality of Life Score (DEQS) | Subjective symptom questionnaire | Change from baseline DEQS at 4 and 12 weeks | |
Secondary | Tear Break Up Time (BUT) | Assessment of BUT in seconds using fluorescein eye drops at the slit lamp. | Change from baseline BUT at 4 and 12 weeks | |
Secondary | Schirmer Test 1 | Wetting of Schirmer test strips within 5 minutes without topical anaesthesia. | Change from Schirmer Test 1 at 4 and 12 weeks | |
Secondary | Tear film osmolarity | Tear film osmolarity will be assessed using the TearLab Osmolarity Test. | Change from baseline tear film osmolarity at 4 and 12 weeks | |
Secondary | Corneal fluorescein staining | Corneal fluorescein staining will be assessed after instillation of fluorescein eye drops at the slit lamp. | Change from baseline corneal fluorescein staining at 4 and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 | |
Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 |